When will the FDA approve Compass Pathways' COMP360 Psilocybin?
2.0 pts (24h)Health & MedicineOne-Off5mo
KalshiCheck availabilityKYC required2% feeVerified resolution dataRoughly calibratedCurrent implied probabilityBefore October 2027 90%Leader of 5 outcomes
Market quality
48 / 100
Low quality24h Volume
$13.4
Liquidity
$7.4K
Medium liquidityBid / Ask
32.0% / 36.0%
Spread
4.0 pt
Moderate spreadMarket data
Updated 19 minutes ago
May 16, 26, 2:30 AMJan 1, 27, 4:59 AM
Trends
Paper funds only — no real moneyNot financial advice
Selected outcome
Before Jan 1, 202736%
Volume trend
$13Jul 220d of dataJul 27
Related Markets
Hantavirus pandemic in 2026?
$120.8KYes: 3%
POLYMARKET
POLYMARKET
# of views of MrBeast video day 3?
$7.4K26-27M: 74%POLYMARKET
POLYMARKET
New pandemic in 2026?
$5.9KYes: 9%POLYMARKET
POLYMARKET
Measles cases in 2026?
$2.8KAbove 3000: 94%KALSHI
KALSHI
Pandemic in 2026?
$2.3KYes: 6%KALSHI
KALSHI
Cyclosporiasis cases reported in the US in 2026?
$1.3KAbove 20k: 34%KALSHI
KALSHIActive in these topics
Rules
If the FDA approves COMP360 Psilocybin for Treatment-Resistant Depression for marketing before Jan 1, 2027, then the market resolves to Yes.
- If the FDA approves COMP360 Psilocybin for Treatment-Resistant Depression for marketing before Mar 1, 2027, then the market resolves to Yes.
- If the FDA approves COMP360 Psilocybin for Treatment-Resistant Depression for marketing before Jul 1, 2027, then the market resolves to Yes.
- If the FDA approves COMP360 Psilocybin for Treatment-Resistant Depression for marketing before Oct 1, 2027, then the market resolves to Yes.
- If the FDA approves COMP360 Psilocybin for Treatment-Resistant Depression for marketing before Jan 1, 2028, then the market resolves to Yes.